Clinical trials
Interstitial Lung Disease clinical trials
Below are recruiting interstitial lung disease clinical trials, each written for real people, not researchers. We’re tracking 194 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06235645Recruiting
Detecting lung disease in rheumatoid arthritis with ultrasound
This study tests if a lung ultrasound can detect early signs of lung disease in people with rheumatoid arthritis. It may help you if you have certain risk factors, like being male, older, or a smoker.
ToursAges 18 years+ - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06068647Recruiting
Ultrasound and breathing tests for lung disease patients
This study uses ultrasound and sensors to monitor lung health in people with certain lung conditions, including those that cause scarring or breathing problems. It aims to find better ways to track lung disease, which could help manage your condition more effectively.
RomeAges 18 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT06036719Recruiting
Lung scarring study from childhood to old age
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
Paris, Île-de-France RegionAges Any age - NCT06053164RecruitingPhase 2
Portable oxygen for activity in mild-to-moderate lung disease
This study is testing whether using portable oxygen during physical activity can help people with mild-to-moderate interstitial lung disease feel better and be more active. It is for people whose oxygen levels drop during exercise but are normal at rest.
Edmonton, AlbertaAges 18–85 - NCT06027333Recruiting
Self-care and outlook in lung scarring
This study looks at how confident and positive people with fibrotic interstitial lung disease feel about managing their condition. It aims to improve support during rehabilitation.
Bern, Canton of BernAges 18 years+ - NCT05986318RecruitingPhase 2
Reducing breathing issues from lung radiation in people with ILD
This trial tests whether a combination of two medications (dexamethasone and N-acetyl cysteine) can reduce breathing problems caused by radiation to lung tumors in patients who have both lung cancer and fibrotic interstitial lung disease (ILD). It aims to find a better way to manage side effects from radiation.
Vancouver, British ColumbiaAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT05854563Recruiting
Study using collected cough samples to learn about lung disease
This trial looks at “cough capture” samples to better understand what is happening in the lungs. You might be eligible if you’re having a bronchoscopy for medical reasons and don’t already have lung cancer.
The Bronx, New YorkAges 21 years+ - NCT05819385Recruiting
Study of lung scarring in immune diseases
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
Mexico CityAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT05727852Enrolling by invitation
Breath and heart tests to study lung disease stiffness
This study uses breath analysis and heart/electrical heart testing to look at how stiff the arteries are in people with long-term lung conditions. It may help researchers better understand lung disease effects on the cardiovascular system.
MoscowAges 18 years+ - NCT05417776RecruitingPhase 2
PET scan test for early lung scarring
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
Boston, MassachusettsAges 40 years+ - NCT05382572Recruiting
Pulmonary fibrosis community registry for patients and families
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
Chicago, IllinoisAges 18 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05120934RecruitingPhase 2
Two medicine doses to reduce ILD cough
This Phase 2 study tests whether two different doses of duloxetine and amitriptyline can reduce coughing caused by interstitial lung disease (ILD). If you have had a long-lasting ILD-related cough despite stable ILD treatment, this trial may help find a better way to control your cough.
Rochester, MinnesotaAges 18–75 - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Phoenix, ArizonaAges Any age - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT04925375RecruitingPhase 2
Abatacept for children with CVID and lung scarring
This Phase 2 trial tests abatacept to improve a specific type of lung disease in children with common variable immunodeficiency (CVID). It aims to slow or reduce ongoing lung changes seen on CT scans while they continue their usual immune “replacement” therapy.
San Francisco, CaliforniaAges 4 years+ - NCT04707781Recruiting
Database study for people at risk of lung scarring
This trial is a study database that collects information from adults who have other illnesses that can increase the risk of developing interstitial lung disease (lung scarring). It may help researchers better understand who is at risk and how outcomes change over time.
GrazAges 18 years+
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for interstitial lung disease?
- Yes. Clin2 currently lists 194 recruiting interstitial lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a interstitial lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.